Literature DB >> 8678768

Adenocarcinoma in the distal esophagus with and without Barrett esophagus. Differences in symptoms and survival rates.

J Johansson1, F Johnsson, B Walther, R Willén, C Staël von Holstein, T Zilling.   

Abstract

OBJECTIVE: To evaluate differences in clinical appearance and survival rates in patients operated on for adenocarcinoma in the distal esophagus with and without Barrett epithelium.
DESIGN: Prospective clinical study.
SETTING: University hospital, Sweden. PATIENTS: Fifty-four patients with adenocarcinoma in the distal esophagus with (n = 17) or without (n = 37) Barrett epithelium. INTERVENTION: Esophagectomy or total gastrectomy. MAIN OUTCOME MEASURES: Preoperative symptoms, endoscopic results, and histological findings; postoperative morbidity, mortality, and survival rates.
RESULTS: The main indication for the endoscopic examination that revealed tumor in the group with Barrett esophagus was reflex-related symptoms in 6 patients (routine Barrett examination, n = 4; symptoms of reflux, n = 2), symptoms related to upper gastrointestinal tract bleeding in 6, and malignant symptoms in 5 (dysphagia, n = 4; weight loss, n = 1). In contrast, most patients in the cardia cancer group were admitted because of malignant symptoms (dysphagia, n = 26; epigastric pain, n = 9; and anemia, n = 2). Ten of 17 patients in the Barrett esophagus cancer group had tumors limited to the mucosa and submucosa only. In 1 patient the tumor grew into the muscular layer but not through it. In the remaining 6 patients the tumor did grow through the muscular layer and lymph node metastases were found. Wall penetration was found in 30 patients and metastases to lymph nodes in 29 patients in the cardia cancer group. The hospital mortality rate was 0 of 17 patients in the Barrett cancer group and 2 of 37 patients in the cardia cancer group. In the patients operated on for adenocarcinoma in the distal esophagus, a better long-term survival rate was seen in those with Barrett epithelium (50%) than in those without this metaplasia (10%) (log rank P = .005; X2 = 7.80).
CONCLUSIONS: Concomitant Barrett epithelium improved the prognosis for patients with adenocarcinoma in the distal esophagus. Probably the reason for this was a higher rate of early-stage disease, because symptoms of gastroesophageal reflux and other benign disorders, not dysphagia, were most common in patients with adenocarcinoma without Barrett epithelium in the distal esophagus.

Entities:  

Mesh:

Year:  1996        PMID: 8678768     DOI: 10.1001/archsurg.1996.01430190030008

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  9 in total

1.  ACP. Best Practice No 155. Guidelines for handling oesophageal biopsies and resection specimens and their reporting.

Authors:  N B Ibrahim
Journal:  J Clin Pathol       Date:  2000-02       Impact factor: 3.411

2.  Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus.

Authors:  J Theisen; H J Stein; H J Dittler; M Feith; C Moebius; W K H Kauer; M Werner; J R Siewert
Journal:  Surg Endosc       Date:  2002-01-09       Impact factor: 4.584

3.  Clinical outcome and long-term survival rates after esophagectomy are not determined by age over 70 years.

Authors:  J Johansson; B Walther
Journal:  J Gastrointest Surg       Date:  2000 Jan-Feb       Impact factor: 3.452

Review 4.  Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?

Authors:  J Lagergren
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

5.  Detection of adenocarcinoma in Barrett's oesophagus by means of laser induced fluorescence.

Authors:  C S von Holstein; A M Nilsson; S Andersson-Engels; R Willén; B Walther; K Svanberg
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

6.  Reliability and validity of a new scale to assess postoperative dysfunction after resection of upper gastrointestinal carcinoma.

Authors:  Misuzu Nakamura; Yoshihiro Kido; Masahiko Yano; Yoshinori Hosoya
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

7.  Use of alarm symptoms to select dyspeptics for endoscopy causes patients with curable esophagogastric cancer to be overlooked.

Authors:  D J Bowrey; S M Griffin; J Wayman; D Karat; N Hayes; S A Raimes
Journal:  Surg Endosc       Date:  2006-10-05       Impact factor: 4.584

Review 8.  Screening for Barrett's Esophagus.

Authors:  Massimiliano di Pietro; Daniel Chan; Rebecca C Fitzgerald; Kenneth K Wang
Journal:  Gastroenterology       Date:  2015-02-17       Impact factor: 22.682

Review 9.  Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma: Implications for Screening and Surveillance.

Authors:  Michael B Cook; Aaron P Thrift
Journal:  Gastrointest Endosc Clin N Am       Date:  2020-10-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.